VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June 30, 2014.
Recent key corporate and clinical developments include:
* Enrolled 54 patients in the Company’s Phase III head and neck cancer trial during the quarter, a 93% increase in sequential quarterly patient enrollment; Subsequently in July, achieved milestone of total 232 patients enrolled to date, representing over one-quarter of the total enrollment for the study.
Help employers find you! Check out all the jobs and post your resume.
